Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.
暂无分享,去创建一个
H L Pearce | M. Sporn | N. Suh | H. Bryant | J. J. Starling | A. Glasebrook | M B Sporn | H U Bryant | A. Palkowitz | Y. Wang | C. Williams | A L Glasebrook | N Suh | A D Palkowitz | L L Burris | J J Starling | C Williams | C Peer | Y Wang | H. Pearce | C. Peer | L. Burris | Y. Wang
[1] S. Cummings,et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.
[2] V. Jordan,et al. Selective oestrogen receptor modulation: molecular pharmacology for the millennium. , 1999, European journal of cancer.
[3] M. Sporn,et al. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. , 1994, Cancer research.
[4] J. Klijn,et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.
[5] V. Jordan,et al. Selective estrogen receptor modulation: a personal perspective. , 2001, Cancer research.
[6] B. Weber,et al. Prophylactic mastectomy--the price of fear. , 1999, The New England journal of medicine.
[7] A. Long,et al. A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.
[8] M. Sporn,et al. A New Ligand for the Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ), GW7845, Inhibits Rat Mammary Carcinogenesis , 1999 .
[9] Shannon K. McDonnell,et al. EFFICACY OF BILATERAL PROPHYLACTIC MASTECTOMY IN WOMEN WITH A FAMILY HISTORY OF BREAST CANCER , 1999 .
[10] Harry Hollema,et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer , 2000, The Lancet.
[11] G. Weryha,et al. Selective estrogen receptor modulators. , 1999, Current opinion in rheumatology.
[12] D. McDonnell,et al. The Molecular Pharmacology of SERMs , 1999, Trends in Endocrinology & Metabolism.
[13] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[14] D. Bentrem,et al. Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] S. Cummings,et al. The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial , 2000 .
[16] B. Gusterson,et al. Comparative study of human and rat mammary tumorigenesis. , 1990, Laboratory investigation; a journal of technical methods and pathology.
[17] J. Gustafsson,et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. , 1997, Endocrinology.
[18] C. Turner,et al. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. , 1998, The Journal of pharmacology and experimental therapeutics.
[19] R. Dickson,et al. ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. , 1989, Cancer research.
[20] T. Rebbeck,et al. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Lippman,et al. Interactions of antiestrogens with human breast cancer in long-term tissue culture. , 1976, Cancer treatment reports.
[22] H. Storm,et al. Endometrial carcinoma and tamoxifen: clearing up a controversy. , 1996, Clinical Cancer Research.
[23] D. Bentrem,et al. Tamoxifen, raloxifene and the prevention of breast cancer. , 2002, Minerva endocrinologica.
[24] M. Lippman,et al. Antiestrogenic effects of LY 117018 in MCF-7 cells. , 1983, Endocrinology.
[25] B. Katzenellenbogen,et al. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. , 1987, Cancer research.
[26] M. Sporn,et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. , 1996, Journal of the National Cancer Institute.